Researchers at Boston University of School of Medicine (BUSM) found that Pramlintide, a relatively new drug used to treat both type 1 and type 2 diabetes, reduces the presence of amyloid-beta peptides, an amino acid that is present in higher levels in the brains of those with Alzheimer’s, and essentially toxic to nerve cells.

Read more